Drs. Meltzer and Jayathilake Reply
J Clin Psychiatry 2008;69(10):1660-1661 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.
Sir: Dr. Jeffrey Mattes’s criticism of the power analysis in
our study is, in part, well taken, if we did not make it sufficiently
clear that dropouts were considered in our original
We had calculated that it was necessary to recruit 40 subjects
per treatment arm in order to achieve 80% power with an expected
25% dropout rate. However, we were unable to recruit
more than 21 and 19 patients in the clozapine and olanzapine